Somewhat Positive Press Coverage Somewhat Unlikely to Impact Brainstorm Cell Therapeutics (BCLI) Share Price

Press coverage about Brainstorm Cell Therapeutics (NASDAQ:BCLI) has trended somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Brainstorm Cell Therapeutics earned a news impact score of 0.24 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.0074477339008 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Several research analysts have recently commented on the stock. ValuEngine raised shares of Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Maxim Group set a $9.00 price objective on shares of Brainstorm Cell Therapeutics and gave the company a “buy” rating in a research note on Wednesday, March 28th.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ BCLI traded down $0.05 during midday trading on Monday, hitting $3.29. The company’s stock had a trading volume of 31,601 shares, compared to its average volume of 62,477. Brainstorm Cell Therapeutics has a 1 year low of $2.88 and a 1 year high of $5.18. The firm has a market cap of $63.69, a price-to-earnings ratio of -12.65 and a beta of 1.86.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings results on Thursday, March 8th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.11. analysts forecast that Brainstorm Cell Therapeutics will post -0.66 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Brainstorm Cell Therapeutics (BCLI) Share Price” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3343783/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-brainstorm-cell-therapeutics-bcli-share-price.html.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd.

Insider Buying and Selling by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Etheroll  Trading Up 58.5% Over Last 7 Days
Etheroll Trading Up 58.5% Over Last 7 Days
Contrasting TransMontaigne  & Shell Midstream Partners
Contrasting TransMontaigne & Shell Midstream Partners
Analyzing Superior Uniform Group  & Lululemon Athletica
Analyzing Superior Uniform Group & Lululemon Athletica
Financial Contrast: Aaron’s  and Its Peers
Financial Contrast: Aaron’s and Its Peers
Emerge Energy Services  Receives $13.14 Consensus PT from Brokerages
Emerge Energy Services Receives $13.14 Consensus PT from Brokerages
Zacks: Analysts Anticipate Key Energy Services  to Announce -$1.24 Earnings Per Share
Zacks: Analysts Anticipate Key Energy Services to Announce -$1.24 Earnings Per Share


Leave a Reply

© 2006-2018 Ticker Report. Google+.